Byoung Chul Cho - Researcher Profile

Publications

4 shown

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok , Yi‐Long Wu , Iveta Kudaba +97 more

2019 The Lancet 3175 citations

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Scott Antonia , Augusto Villegas , Davey B. Daniel +30 more

Durvalumab therapy resulted in significantly longer overall survival than placebo. No new safety signals were identified. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov numb...

2018 New England Journal of Medicine 2682 citations

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam , Johan Vansteenkiste , David Planchard +21 more

Among patients with previously untreated advanced NSCLC with an <i>EGFR</i> mutation, those who received osimertinib had longer overall survival than those who received a compar...

2019 New England Journal of Medicine 2577 citations

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele , Alexander Drilon , Luis Paz‐Ares +35 more

Ignyta/F Hoffmann-La Roche.

2019 The Lancet Oncology 1625 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 5
Citations: 13,234
Institution: Yonsei University

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-5562-270X

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.